EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische Studie

Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial

Devin Schellenberg, Zsolt Gabos, Adele Duimering, Brock Debenham, Alysa Fairchild, Fleur Huang, Lindsay S Rowe, Diane Severin, Meredith E Giuliani, Andrea Bezjak, Benjamin H Lok, Srinivas Raman und 20 weitere

International Journal of Radiation Oncology*Biology*Physics · 2025-01 · 121 (1) · 28-38

DOI: 10.1016/j.ijrobp.2024.08.031 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025-01. Verfasst von Devin Schellenberg und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, BC Cancer - Surrey, Surrey, British Columbia, Canada. Electronic address: dschellenberg@bccancer.bc.ca. Hauptthemen laut MEDLINE: Radiosurgery, Lung Neoplasms, Disease Progression, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: London Health Sciences Foundation, Ontario Institute for Cancer Research, Government of Ontario.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This trial examined if patients with ≤5 sites of oligoprogression benefit from the addition of SABR to standard of care (SOC) systemic therapy. METHODS AND MATERIALS: We enrolled patients with 1 to 5 metastases progressing on systemic therapy, and after stratifying by type of systemic therapy (cytotoxic vs noncytotoxic), randomized 1:2 between continued SOC treatment versus SABR to all progressing lesions plus SOC. The trial was initially limited to non-small cell lung cancer but was expanded to include all nonhematologic malignancies to meet accrual goals. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), lesional control, quality of life, adverse events, and duration of systemic therapy postrandomization. RESULTS: Ninety patients with 127 oligoprogressive metastases were enrolled across 8 Canadian institutions, with 59 randomized to SABR and 31 to SOC. The median age was 67 years, and 39 (43%) were women. The most common primary sites were lung (44%), genitourinary (23%), and breast (13%). Protocol adherence in the SOC arm was suboptimal, with 11 patients (35%) either receiving high-dose/ablative therapies (conflicting with trial protocol) or withdrawing from the study. The median follow-up was 31 months. There was no difference in PFS between arms (median PFS 8.4 months in the SABR arm vs 4.3 months in the SOC arm, but curves cross and 2-year PFS was 9% vs 24%, respectively; P = .91). The median OS was 31.2 months versus 27.4 months, respectively (P = .22). Lesional control was superior with SABR (70% vs 38%, respectively; P = .0015). There were 2 (3.4%) grade 3 and no grade 4/5 adverse events attributable to SABR. CONCLUSIONS: SABR was well-tolerated with superior lesional control but did not improve PFS or OS. Accrual to this study was difficult, and the results may have been impacted by an unwillingness to forgo ablative treatments on the SOC arm. (NCT02756793).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgeryLung NeoplasmsDisease ProgressionCarcinoma, Non-Small-Cell LungHumansFemaleMaleAgedMiddle AgedAged, 80 and overProgression-Free SurvivalQuality of LifeAdultStandard of CareBreast NeoplasmsEarly Termination of Clinical TrialsNeoplasmsUrogenital Neoplasms

Autor:innen und Institutionen

  • Department of Radiation Oncology, BC Cancer - Surrey, Surrey, British Columbia, Canada. Electronic address: dschellenberg@bccancer.bc.ca.
  • University of Alberta, Edmonton, Alberta, Canada.
  • Department of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Department of Radiation Oncology, BC Cancer - Surrey, Surrey, British Columbia, Canada.
  • Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada.
  • Department of Radiation Oncology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Förderung

  • London Health Sciences Foundation
  • Ontario Institute for Cancer Research
  • Government of Ontario

Zitieren

APA

Schellenberg, D., Gabos, Z., Duimering, A., Debenham, B., Fairchild, A., Huang, F., Rowe, L. S., Severin, D., Giuliani, M. E., Bezjak, A., Lok, B. H., Raman, S., Chung, P., Zhao, Y., Ho, C. K., Lock, M., Louie, A. V., Lefresne, S., Carolan, H., …, & Palma, D. A. (2025). Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial. International Journal of Radiation Oncology*Biology*Physics, 121(1), 28-38. https://doi.org/10.1016/j.ijrobp.2024.08.031

Vancouver

Schellenberg D, Gabos Z, Duimering A, Debenham B, Fairchild A, Huang F, et al. Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial. International Journal of Radiation Oncology*Biology*Physics. 2025;121(1):28-38. doi:10.1016/j.ijrobp.2024.08.031

BibTeX
@article{Schellenberg2025,
  author = {Schellenberg, Devin and Gabos, Zsolt and Duimering, Adele and Debenham, Brock and Fairchild, Alysa and Huang, Fleur and Rowe, Lindsay S and Severin, Diane and Giuliani, Meredith E and Bezjak, Andrea and Lok, Benjamin H and Raman, Srinivas and Chung, Peter and Zhao, Yizhou and Ho, Clement K and Lock, Michael and Louie, Alexander V and Lefresne, Shilo and Carolan, Hannah and Liu, Mitchell and Yau, Vivian and Ye, Allison and Olson, Robert A and Mou, Benjamin and Mohamed, Islam G and Petrik, David W and Dosani, Maryam and Pai, Howard and Valev, Boris and Gaede, Stewart and Warner, Andrew and Palma, David A},
  title = {Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2025},
  volume = {121},
  number = {1},
  pages = {28--38},
  doi = {10.1016/j.ijrobp.2024.08.031}
}
Kostenlos starten →